# To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

> **NCT06940336** · PHASE4 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Transthyretin Amyloid Polyneuropathy

## Interventions

- **DRUG:** Tafamidis Meglumine Soft Capsules

## Key facts

- **NCT ID:** NCT06940336
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-19
- **Primary completion:** 2028-01
- **Final completion:** 2028-02
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940336, "To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06940336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*